JY09 / Beijing Eastern Biotech - LARVOL DELTA

DFBT-JY09-DM-301: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients (clinicaltrials.gov) - P3 | N=270 | Active, not recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Apr 2025 ➔ May 2026

Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

DFBT-JY09-DM-302: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (clinicaltrials.gov) - P3 | N=600 | Active, not recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Nov 2026 | Trial primary completion date: Apr 2025 ➔ Oct 2026

Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

DFBT-JY09-DM-302: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Jul 2024

Combination therapy • Enrollment open • Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

DFBT-JY09-DM-301: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients (clinicaltrials.gov) - P3 | N=270 | Recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Jul 2024

Enrollment open • Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd.

Combination therapy • New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

DFBT-JY09-DM-301: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients (clinicaltrials.gov) - P3 | N=270 | Not yet recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd.

New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09 (clinicaltrials.gov) - P1; N=41; Completed; Sponsor: Beijing Dongfang Biotech Co., Ltd.

Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus